Divi’s Laboratories Limited reported consolidated net profit of ₹1,127 crore for the quarter ended Sept. 30, up 63.6% from a year earlier, alongside a 35.4% increase in operating revenue.
Revenue from operations totaled ₹3,676 crore, compared with ₹2,715 crore in the same quarter a year ago. Earnings before interest, taxes, depreciation and amortization (EBITDA) reached ₹1,566 crore, up from ₹888 crore, a 76% year-over-year increase.
The consolidated EBITDA margin — EBITDA as a share of revenue — was 42.6%, compared with 32.7% in the year-earlier quarter. The company’s unaudited results also showed other income falling to ₹94 crore from ₹145 crore and foreign-exchange gains declining to ₹24 crore from ₹63 crore.
Tax expense was ₹378 crore, up from ₹223 crore a year earlier. The results did not identify what drove the increases in revenue or EBITDA margin.
The standalone statements show quarterly profit of ₹1,140 crore and revenue from operations of ₹3,647 crore. Those amounts differ from the consolidated results, which include profit of ₹1,127 crore and revenue of ₹3,676 crore.
The board approved unaudited results for the quarter and half year ended Sept. 30, 2026, and the filing included statutory auditors’ limited-review reports. Divi’s makes active pharmaceutical ingredients, intermediates and nutraceutical ingredients; the company reports one business segment.
